Covered recipient · General Payments record
SANOBER KABLE
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$32,971.88
287 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,975.00 | 17 |
| Food and Beverage | $4,312.88 | 267 |
| Consulting Fee | $600.00 | 1 |
| Travel and Lodging | $84.00 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $17,297.20 | 67 |
| AstraZeneca Pharmaceuticals LP | $7,968.39 | 23 |
| United Therapeutics Corporation | $4,171.93 | 12 |
| Takeda Pharmaceuticals U.S.A., Inc. | $788.07 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $451.95 | 30 |
| JAZZ PHARMACEUTICALS INC. | $318.01 | 17 |
| Electromed, Inc. | $302.73 | 27 |
| Actelion Pharmaceuticals US, Inc. | $220.37 | 12 |
| Grifols USA, LLC | $179.94 | 10 |
| Mylan Specialty L.P. | $168.93 | 20 |
| Regeneron Healthcare Solutions, Inc. | $167.99 | 11 |
| Ethicon Inc. | $139.91 | 1 |
| Janssen Pharmaceuticals, Inc | $131.15 | 3 |
| Sunovion Pharmaceuticals Inc. | $127.06 | 12 |
| GENZYME CORPORATION | $93.15 | 4 |
| Novartis Pharmaceuticals Corporation | $87.23 | 5 |
| Bayer HealthCare Pharmaceuticals Inc. | $53.57 | 3 |
| Philips Electronics North America Corporation | $49.37 | 3 |
| Insmed, Inc. | $45.91 | 3 |
| Genentech USA, Inc. | $43.69 | 3 |
| Advanced Respiratory, Inc | $41.57 | 2 |
| HARMONY BIOSCIENCES LLC | $40.30 | 2 |
| Eisai Inc. | $34.99 | 2 |
| Gilead Sciences, Inc. | $32.54 | 2 |
| Merck Sharp & Dohme Corporation | $15.93 | 1 |
Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SANOBER KABLE
NPI 1295876399 · CMS profile ID 331455
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
DENISON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SANOBER KABLE, NPI 1295876399, CMS profile ID 331455. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SANOBER KABLE, NPI 1295876399, CMS profile ID 331455. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SANOBER KABLE, NPI 1295876399, CMS profile ID 331455, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
287 matching records · $32,971.88 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 287.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.39 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763540186 | CMS |
| JAZZ PHARMACEUTICALS INC. | $25.00 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845549959 | CMS |
| Electromed, Inc. | $8.87 | 04/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849607329 | CMS |
| JAZZ PHARMACEUTICALS INC. | $9.44 | 04/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845586467 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 04/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802944981 | CMS |
| Grifols USA, LLC | $16.81 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846763535 | CMS |
| United Therapeutics Corporation | $1,435.00 | 04/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839136685 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.80 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763540188 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.20 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763540190 | CMS |
| Mylan Specialty L.P. | $10.45 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965410685 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $10.71 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820003517 | CMS |
| GlaxoSmithKline, LLC. | $0.78 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801669169 | CMS |
| GlaxoSmithKline, LLC. | $4.49 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803050616 | CMS |
| Grifols USA, LLC | $16.54 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846780555 | CMS |
| JAZZ PHARMACEUTICALS INC. | $5.24 | 04/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845579827 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.07 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763540192 | CMS |
| Electromed, Inc. | $12.95 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849607331 | CMS |
| GlaxoSmithKline, LLC. | $11.23 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802044187 | CMS |
| Actelion Pharmaceuticals US, Inc. | $20.16 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788088891 | CMS |
| Mylan Specialty L.P. | $4.67 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965409003 | CMS |
| GlaxoSmithKline, LLC. | $9.71 | 04/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801673711 | CMS |
| Novartis Pharmaceuticals Corporation | $15.28 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812737765 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.13 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763540194 | CMS |
| Sunovion Pharmaceuticals Inc. | $9.34 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821898175 | CMS |
| GlaxoSmithKline, LLC. | $11.13 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801907043 | CMS |
| GlaxoSmithKline, LLC. | $14.50 | 03/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802978793 | CMS |
| GlaxoSmithKline, LLC. | $8.43 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801670639 | CMS |
| Regeneron Healthcare Solutions, Inc. | $18.50 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809590943 | CMS |
| GlaxoSmithKline, LLC. | $4.23 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801670477 | CMS |
| Mylan Specialty L.P. | $11.06 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965407329 | CMS |
| Electromed, Inc. | $11.07 | 03/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849607325 | CMS |
| GENZYME CORPORATION | $19.33 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843614987 | CMS |
| Actelion Pharmaceuticals US, Inc. | $20.90 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788088889 | CMS |
| GlaxoSmithKline, LLC. | $6.20 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802948497 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.58 | 03/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763540196 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $19.32 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789095503 | CMS |
| Sunovion Pharmaceuticals Inc. | $19.11 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821685177 | CMS |
| JAZZ PHARMACEUTICALS INC. | $23.17 | 03/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845588567 | CMS |
| Electromed, Inc. | $9.44 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849607323 | CMS |
| GlaxoSmithKline, LLC. | $4.81 | 03/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1119249374 | CMS |
| Sunovion Pharmaceuticals Inc. | $17.97 | 03/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821722257 | CMS |
| Sunovion Pharmaceuticals Inc. | $5.00 | 03/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821928153 | CMS |
| Mylan Specialty L.P. | $8.15 | 03/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965404077 | CMS |
| JAZZ PHARMACEUTICALS INC. | $4.96 | 02/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845579825 | CMS |
| Actelion Pharmaceuticals US, Inc. | $26.49 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788088895 | CMS |
| GlaxoSmithKline, LLC. | $7.33 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802920149 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.90 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809590941 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10.95 | 02/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763540198 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.61 | 02/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834346359 | CMS |
| Electromed, Inc. | $7.76 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849607317 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $130,712.81 | 58 |
| PY2024 | Principal investigator | $400,767.02 | 106 |
| PY2023 | Principal investigator | $116,399.43 | 34 |
| PY2022 | Principal investigator | $17,554.61 | 6 |
| PY2021 | Principal investigator | $15,782.65 | 3 |
| PY2019 | Recipient | $1,400.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
58 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278242 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278244 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278252 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278254 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/19/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278256 |
| Principal investigator 1 | Insmed, Inc. | $977.60 | 11/14/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648438 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,000.00 | 10/30/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184256143 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 10/30/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184256145 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,200.00 | 10/30/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184256147 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $29.21 | 10/23/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184253138 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $42.19 | 10/23/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184253140 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,000.00 | 10/22/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine Pa | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype | No dispute reported | 06/30/2026 | 1226104865 |
| Principal investigator 1 | Insmed, Inc. | $9,998.82 | 10/17/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648440 |
| Principal investigator 1 | United Therapeutics Corporation | $3,331.65 | 10/06/2025 | Non-covered Recipient Entity Premier Pulmonary cc and sleep Medicine | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242387569 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $301.61 | 07/16/2025 | Non-covered Recipient Entity PREMIER PULMONARY | A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy | No dispute reported | 06/30/2026 | 1185545211 |
| Principal investigator 1 | United Therapeutics Corporation | $1,500.00 | 07/04/2025 | Non-covered Recipient Entity Premier Pulmonary cc and sleep Medicine | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242387567 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,567.15 | 06/23/2025 | Non-covered Recipient Entity CARDIOVOYAGE LLC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185545213 |
| Principal investigator 1 | Cumberland Pharmaceuticals, Inc. | $12,228.75 | 06/10/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE | ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | No dispute reported | 06/30/2026 | 1242141379 |
| Principal investigator 1 | Cumberland Pharmaceuticals, Inc. | $13,350.00 | 06/10/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE | ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | No dispute reported | 06/30/2026 | 1242141383 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,510.00 | 04/28/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine Admin | BAY 632521, RiOciguAt UseRs Registry The ROAR registry | No dispute reported | 06/30/2026 | 1225419861 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,590.00 | 04/28/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine Admin | BAY 632521, RiOciguAt UseRs Registry The ROAR registry | No dispute reported | 06/30/2026 | 1225419875 |
| Principal investigator 1 | Insmed, Inc. | $870.48 | 03/31/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648434 |
| Principal investigator 1 | Insmed, Inc. | $209.43 | 03/31/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648436 |
| Principal investigator 1 | Insmed, Inc. | $0.22 | 03/19/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648390 |
| Principal investigator 1 | Insmed, Inc. | $1.38 | 03/19/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648398 |
| Principal investigator 1 | Insmed, Inc. | $1.38 | 03/19/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648404 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 03/17/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648394 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 03/17/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648400 |
| Principal investigator 1 | Insmed, Inc. | $0.92 | 03/17/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648406 |
| Principal investigator 1 | Insmed, Inc. | $1,251.90 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648408 |
| Principal investigator 1 | Insmed, Inc. | $1,210.95 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648410 |
| Principal investigator 1 | Insmed, Inc. | $1,088.10 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648412 |
| Principal investigator 1 | Insmed, Inc. | $1,088.10 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648414 |
| Principal investigator 1 | Insmed, Inc. | $209.43 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648416 |
| Principal investigator 1 | Insmed, Inc. | $152.10 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648418 |
| Principal investigator 1 | Insmed, Inc. | $209.43 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648420 |
| Principal investigator 1 | Insmed, Inc. | $209.43 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648422 |
| Principal investigator 1 | Insmed, Inc. | $42.12 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648424 |
| Principal investigator 1 | Insmed, Inc. | $152.10 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648426 |
| Principal investigator 1 | Insmed, Inc. | $152.10 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648428 |
| Principal investigator 1 | Insmed, Inc. | $152.10 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648430 |
| Principal investigator 1 | Insmed, Inc. | $40.95 | 02/21/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648432 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,500.00 | 01/28/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | No dispute reported | 06/30/2026 | 1192169587 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 01/28/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | No dispute reported | 06/30/2026 | 1192169591 |
| Principal investigator 1 | Insmed, Inc. | $0.66 | 01/16/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648386 |
| Principal investigator 1 | Insmed, Inc. | $9,185.12 | 01/16/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648392 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 01/16/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648396 |
| Principal investigator 1 | Insmed, Inc. | $1.38 | 01/16/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648402 |
| Principal investigator 1 | Insmed, Inc. | $0.88 | 01/13/2025 | Non-covered Recipient Entity Premier Pulmonary Critical Care And Sleep Medicine PA | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189648388 |
| Principal investigator 1 | United Therapeutics Corporation | $1,500.00 | 01/09/2025 | Non-covered Recipient Entity Premier Pulmonary cc and sleep Medicine | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | No dispute reported | 06/30/2026 | 1242387565 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,711.41 | 01/08/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185545209 |
| Principal investigator 1 | Cumberland Pharmaceuticals, Inc. | $7,500.00 | 01/03/2025 | Non-covered Recipient Entity PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE | ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | No dispute reported | 06/30/2026 | 1242141244 |